Clopidogrel withdrawal: is there a "rebound" phenomenon?

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis Research

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for acute coronary syndromes and following percutaneous coronary intervention.
• Current guidelines recommend lifelong aspirin and 1-12 months of clopidogrel, but optimal duration remains debated.
• Premature clopidogrel cessation increases stent thrombosis risk; even appropriate cessation may be linked to adverse clinical events.

Purpose of the Study:

• To define and explore the "rebound" phenomenon after clopidogrel cessation.
• To investigate the mechanisms underlying this potential prothrombotic and proinflammatory response.
• To discuss the clinical implications of clopidogrel withdrawal and future antiplatelet therapy strategies.

Main Methods:

• Review of existing clinical studies and literature.
• Examination of proposed pathophysiological mechanisms for clopidogrel rebound.
• Analysis of clopidogrel's antiplatelet and anti-inflammatory properties, including effects on arachidonic acid pathways.

Main Results:

• Evidence suggests a potential "rebound" prothrombotic/proinflammatory state upon clopidogrel withdrawal.
• Clustering of adverse clinical events observed after both premature and "appropriate" cessation.
• Clopidogrel exhibits anti-inflammatory effects beyond traditional aspirin targets.

Conclusions:

• The optimal duration of clopidogrel therapy requires further investigation due to potential rebound effects.
• Understanding clopidogrel's mechanisms is crucial for managing cardiovascular risk post-cessation.
• Newer antiplatelet agents and revised guidelines may alter future DAPT strategies.